Progyny (PGNY)
(Delayed Data from NSDQ)
$16.10 USD
-0.35 (-2.13%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.10 USD
-0.35 (-2.13%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
Zacks News
UnitedHealth (UNH) Rewards Shareholders With 13.8% Dividend Hike
by Zacks Equity Research
UnitedHealth's (UNH) strong balance sheet supports its endeavors to return shareholders' funds.
Encompass Health (EHC) Updates 2022 Guidance: Dips 5.4%
by Zacks Equity Research
Encompass Health (EHC) expects to retain its cash dividend routine. However, the amount might decline to reflect the spin-off of the home health and hospice business.
Ensign Group (ENSG) Up 3.7% in 30 Days: More Room to Rally?
by Zacks Equity Research
Ensign Group's (ENSG) rising profits from Skilled Services business are a major positive.
HCA Healthcare's (HCA) Utah Acquisition Faces Fed Roadblocks
by Zacks Equity Research
The trade watchdog expects HCA Healthcare's (HCA) Utah acquisition to induce market concentration and eliminate Steward Health Care as a low-cost competitor.
Implied Volatility Surging for Progyny (PGNY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Progyny (PGNY) stock based on the movements in the options market lately.
AMN vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%
by Zacks Equity Research
The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.
Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 150% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Progyny (PGNY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVTR vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVTR vs. PGNY: Which Stock Is the Better Value Option?
OCDX vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCDX vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 275% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Progyny (PGNY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny (PGNY) Q3 Earnings Beat Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 142.86% and -2.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
by Zacks Equity Research
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
5 Medical Services Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most. However, falling healthcare spending may disrupt the trend.
Progyny (PGNY) Beats Q2 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 111.11% and -0.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny (PGNY) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured highlights include: Digital Turbine, 360 DigiTech, Progyny and E.W. Scripps
by Zacks Equity Research
Zacks.com featured highlights include: Digital Turbine, 360 DigiTech, Progyny and E.W. Scripps
4 Stocks With High Net Income Ratio to Scoop Up
by Nitish Marwah
APPS, QFIN, PGNY, and SSP have qualified the screen for high net income ratio stocks.
Progyny (PGNY) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Progyny (PGNY) has been struggling lately, but the selling pressure may be coming to an end soon.